Alzheimer's research shows promise in mice but human applicability remains unproven

University of South Carolina researchers developed a nanoparticle treatment that reverses cognitive decline in Alzheimer's mouse models within weeks, but human trials are still years away.

University of South Carolina researchers created Nano-ERASER, a nanoparticle treatment targeting polypyrimidine tract-binding protein 1 (PTBP1) to convert astrocytes into neurons. In animal models of Alzheimer's disease, a single injection reversed cognitive decline within weeks, with treated mice showing improved nesting behavior and maze navigation compared to controls. Two injections during the treatment period produced measurable cognitive improvements, even in mice without Alzheimer's disease models. The research was published in *Cell Biomaterials*. However, the current animal model results lack human applicability for Alzheimer's treatment, and the potential application for advanced dementia patients remains unproven in humans. This work demonstrates a biological mechanism that could theoretically restore memory function in dementia, but it does not yet translate to human patients. What matters next is whether human trials can bridge this gap—specifically, whether the nanoparticle’s effects on brain cell conversion scale to human cognition. Until then, this remains a promising but distant possibility for memory restoration in Alzheimer’s disease.

Source: New Atlas